The FDA has approved Harmony Biosciences' Wakix (pitolisant) for treating cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.
The FDA has approved pitolisant tablets for treating cataplexy in pediatric patients aged 6 and older with narcolepsy, making it the only non-scheduled therapy approved for both pediatric and adult narcolepsy patients with or without cataplexy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07250633 |
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT05224609 |
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction |
COMPLETED | PHASE1 |
| NCT05199610 |
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143 |
COMPLETED | PHASE1 |
| NCT05116826 |
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients |
COMPLETED | PHASE1 |
| NCT03865446 |
Evaluate Severe Hepatic Impairment on Dacomitinib PK |
COMPLETED | PHASE1 |
| NCT03818672 |
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects |
TERMINATED | PHASE4 |
| NCT03664544 |
PK Study in Subjects With Severe Hepatic Impairment |
COMPLETED | PHASE1 |
| NCT02170220 |
Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment |
COMPLETED | PHASE1 |
| NCT02138162 |
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men |
COMPLETED | PHASE1 |
